NCT01471990

Effect of PACAP38/VIP on Migraineurs Measured by Magnetic Resonance

The Effect of PACAP38 and VIP on Migraine Patients Assessed by a 3-Tesla MR Scanner

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 24 (actual)
• Sponsor: Glostrup University Hospital, Copenhagen · Academic / Other
• Sex: All
• Age: 18 Years – 40 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to examine and compare the effect of pituitary adenylate cyclase-activating polypeptide-38 (PACAP38) and vasoactive intestinal polypeptide (VIP) on intracranial arteries and neuronal activity in patients with migraine without aura using a high resolution magnetic resonance imaging (MRI), including MR angiography (MRA) and functional MRI (fMRI). MRA will be used to detect changes in intracranial artery circumferences before and after PACAP38 and VIP. fMRI will be used oo detect changes in blood-oxygenation-level-dependent-signal (BOLD-signal). PACAP38 but not VIP induces migraine like attacks in migraine patients. The migraine specific drug sumatriptan will be given to relieve pain and the effect will also be registered using MRA and fMRI.

Conditions

• Migraine Without Aura

Interventions

Type	Name	Description
DRUG	Pituitary Adenylate Cyclase-Activating Polypeptide-38	10 pmol/kg/min over 20 mins
DRUG	Vasoactive Intestinal Peptide	8 pmol/kg/min over 20 mins

Timeline

• Start date: 2011-05-01
• Primary completion: 2012-06-01
• Completion: 2012-06-01
• First posted: 2011-11-16
• Last updated: 2012-08-29

Locations

1 site across 1 country: Denmark